Latest news with #RAPTTherapeutics
Business Insider
4 days ago
- Business
- Business Insider
RAPT Therapeutics (RAPT) Has a New Rating from Clear Street
RAPT Therapeutics (RAPT – Research Report) received a Buy rating and a $3.00 price target from Clear Street analyst Kaveri Pohlman yesterday. The company's shares closed yesterday at $1.02. Confident Investing Starts Here: Pohlman covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Akero Therapeutics, and RAPT Therapeutics. According to TipRanks, Pohlman has an average return of -12.3% and a 27.06% success rate on recommended stocks. RAPT Therapeutics has an analyst consensus of Hold, with a price target consensus of $3.75, which is a 267.65% upside from current levels. In a report released on May 22, H.C. Wainwright also reiterated a Buy rating on the stock with a $6.00 price target.
Yahoo
18-04-2025
- Business
- Yahoo
Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse. Given this risk, we thought we'd take a look at whether RAPT Therapeutics (NASDAQ:RAPT) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company spends each year to fund its growth. Let's start with an examination of the business' cash, relative to its cash burn. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. A company's cash runway is calculated by dividing its cash hoard by its cash burn. When RAPT Therapeutics last reported its December 2024 balance sheet in March 2025, it had zero debt and cash worth US$231m. Looking at the last year, the company burnt through US$83m. So it had a cash runway of about 2.8 years from December 2024. Arguably, that's a prudent and sensible length of runway to have. You can see how its cash balance has changed over time in the image below. See our latest analysis for RAPT Therapeutics Because RAPT Therapeutics isn't currently generating revenue, we consider it an early-stage business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. With cash burn dropping by 15% it seems management feel the company is spending enough to advance its business plans at an appropriate pace. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company. While RAPT Therapeutics is showing a solid reduction in its cash burn, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Commonly, a business will sell new shares in itself to raise cash and drive growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate). Since it has a market capitalisation of US$106m, RAPT Therapeutics' US$83m in cash burn equates to about 79% of its market value. That's very high expenditure relative to the company's size, suggesting it is an extremely high risk stock. Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought RAPT Therapeutics' cash runway was relatively promising. Even though we don't think it has a problem with its cash burn, the analysis we've done in this article does suggest that shareholders should give some careful thought to the potential cost of raising more money in the future. On another note, we conducted an in-depth investigation of the company, and identified 5 warning signs for RAPT Therapeutics (3 don't sit too well with us!) that you should be aware of before investing here. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies with significant insider holdings, and this list of stocks growth stocks (according to analyst forecasts) Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
